POZEN’s therapeutic development programs qualified to receive federal grant under PPACA

Nov 3 2010

POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to transforming medicine that transforms lives, today announced that three of the Company's therapeutic development programs, VIMOVO™ (naproxen / esomeprazole magnesium) (formerly PN400), PA32540 and PA65020, qualified to receive federal grant funding under The Patient Protection and Affordable Care Act. As a result, the Company will receive a non-taxable cash grant totaling approximately $730,000, which will be recorded as income in the 2010 fourth quarter.

“We are pleased that our efforts and innovations are being rewarded. We will continue to advance the development of our integrated aspirin portfolio and look forward to the day when these products are approved and patients in need have access to them”

The Patient Protection and Affordable Care Act created a $1.0 billion federal program to reimburse and/or subsidize certain costs paid or incurred in calendar 2009 and 2010 directly related to the conduct of a "Qualifying Therapeutic Discovery Project." The Department of Health and Human Services (HHS) designates such projects based on the potential to produce new cost-saving therapies, support jobs, and increase U.S. competitiveness.

"We are pleased that our efforts and innovations are being rewarded. We will continue to advance the development of our integrated aspirin portfolio and look forward to the day when these products are approved and patients in need have access to them," said John Plachetka, Chairman, President and Chief Executive Officer of POZEN.